On the other hand, SEMA3A secreted by a variety of human tumor cells (lung, breast, prostate, glioblastoma, and colorectal cancer cells) has been shown to inhibit tumor-CD4+/CD8+ lymphocyte interactions and T-cell activation and proliferation [97]. This evidence concerns the gene CD4 and neoplasm.